These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

169 related items for PubMed ID: 29072615

  • 1. The Novel Triazolonaphthalimide Derivative LSS-11 Synergizes the Anti-Proliferative Effect of Paclitaxel via STAT3-Dependent MDR1 and MRP1 Downregulation in Chemoresistant Lung Cancer Cells.
    Ji L, Liu X, Zhang S, Tang S, Yang S, Li S, Qi X, Yu S, Lu L, Meng X, Liu Z.
    Molecules; 2017 Oct 26; 22(11):. PubMed ID: 29072615
    [Abstract] [Full Text] [Related]

  • 2.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4. Schisandrin A reverses doxorubicin-resistant human breast cancer cell line by the inhibition of P65 and Stat3 phosphorylation.
    Zhang ZL, Jiang QC, Wang SR.
    Breast Cancer; 2018 Mar 26; 25(2):233-242. PubMed ID: 29181822
    [Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7. YAN, a novel microtubule inhibitor, inhibits P-gp and MRP1 function and induces mitotic slippage followed by apoptosis in multidrug-resistant A549/Taxol cells.
    Gao M, Liu T, Li J, Guan Q, Wang H, Yan S, Li Z, Zuo D, Zhang W, Wu Y.
    Toxicol In Vitro; 2020 Dec 26; 69():104971. PubMed ID: 32805372
    [Abstract] [Full Text] [Related]

  • 8. LncRNA-MALAT1 contributes to the cisplatin-resistance of lung cancer by upregulating MRP1 and MDR1 via STAT3 activation.
    Fang Z, Chen W, Yuan Z, Liu X, Jiang H.
    Biomed Pharmacother; 2018 May 26; 101():536-542. PubMed ID: 29505924
    [Abstract] [Full Text] [Related]

  • 9. [Correlation of chemosensitivity measured by histoculture drug response assay to expression of multidrug resistance genes and proteins in gastric cancer].
    Yuan SQ, Zhou ZW, Liang YJ, Fu LW, Chen G, Keshari RP, Zhang LY.
    Ai Zheng; 2009 Apr 26; 28(4):337-43. PubMed ID: 19622290
    [Abstract] [Full Text] [Related]

  • 10. SH003 reverses drug resistance by blocking signal transducer and activator of transcription 3 (STAT3) signaling in breast cancer cells.
    Seo HS, Ku JM, Lee HJ, Woo JK, Cheon C, Kim M, Jang BH, Shin YC, Ko SG.
    Biosci Rep; 2017 Dec 22; 37(6):. PubMed ID: 28864784
    [Abstract] [Full Text] [Related]

  • 11. Reversal of multidrug resistance by icaritin in doxorubicin-resistant human osteosarcoma cells.
    Wang ZD, Wang RZ, Xia YZ, Kong LY, Yang L.
    Chin J Nat Med; 2018 Jan 22; 16(1):20-28. PubMed ID: 29425587
    [Abstract] [Full Text] [Related]

  • 12. Reversal of multidrug resistance by Marsdenia tenacissima and its main active ingredients polyoxypregnanes.
    To KKW, Wu X, Yin C, Chai S, Yao S, Kadioglu O, Efferth T, Ye Y, Lin G.
    J Ethnopharmacol; 2017 May 05; 203():110-119. PubMed ID: 28363522
    [Abstract] [Full Text] [Related]

  • 13. Increased MDR1 expression in normal and malignant peripheral blood mononuclear cells obtained from patients receiving depsipeptide (FR901228, FK228, NSC630176).
    Robey RW, Zhan Z, Piekarz RL, Kayastha GL, Fojo T, Bates SE.
    Clin Cancer Res; 2006 Mar 01; 12(5):1547-55. PubMed ID: 16533780
    [Abstract] [Full Text] [Related]

  • 14. Timosaponin A-III reverses multi-drug resistance in human chronic myelogenous leukemia K562/ADM cells via downregulation of MDR1 and MRP1 expression by inhibiting PI3K/Akt signaling pathway.
    Chen JR, Jia XH, Wang H, Yi YJ, Wang JY, Li YJ.
    Int J Oncol; 2016 May 01; 48(5):2063-70. PubMed ID: 26984633
    [Abstract] [Full Text] [Related]

  • 15. [Molecular mechanism of cisplatin to enhance the ability of TRAIL in reversing multidrug resistance in gastric cancer cells].
    Zhu X, Zhang K, Wang Q, Chen S, Gou Y, Cui Y, Li Q.
    Zhonghua Zhong Liu Za Zhi; 2015 Jun 01; 37(6):404-11. PubMed ID: 26463141
    [Abstract] [Full Text] [Related]

  • 16. Cinnamaldehyde derivative (CB-PIC) sensitizes chemo-resistant cancer cells to drug-induced apoptosis via suppression of MDR1 and its upstream STAT3 and AKT signalling.
    Yun M, Lee D, Park MN, Kim EO, Sohn EJ, Kwon BM, Kim SH.
    Cell Physiol Biochem; 2015 Jun 01; 35(5):1821-30. PubMed ID: 25833196
    [Abstract] [Full Text] [Related]

  • 17. RNA expression of breast cancer resistance protein, lung resistance-related protein, multidrug resistance-associated proteins 1 and 2, and multidrug resistance gene 1 in breast cancer: correlation with chemotherapeutic response.
    Burger H, Foekens JA, Look MP, Meijer-van Gelder ME, Klijn JG, Wiemer EA, Stoter G, Nooter K.
    Clin Cancer Res; 2003 Feb 01; 9(2):827-36. PubMed ID: 12576456
    [Abstract] [Full Text] [Related]

  • 18. BZML, a novel colchicine binding site inhibitor, overcomes multidrug resistance in A549/Taxol cells by inhibiting P-gp function and inducing mitotic catastrophe.
    Bai Z, Gao M, Zhang H, Guan Q, Xu J, Li Y, Qi H, Li Z, Zuo D, Zhang W, Wu Y.
    Cancer Lett; 2017 Aug 28; 402():81-92. PubMed ID: 28576750
    [Abstract] [Full Text] [Related]

  • 19. Chemoresistance of Lung and Breast Cancer Cells Growing Under Prolonged Periods of Serum Starvation.
    Yakisich JS, Venkatadri R, Azad N, Iyer AKV.
    J Cell Physiol; 2017 Aug 28; 232(8):2033-2043. PubMed ID: 27504932
    [Abstract] [Full Text] [Related]

  • 20. (-)-Epigallocatechin-3-gallate downregulates Pg-P and BCRP in a tamoxifen resistant MCF-7 cell line.
    Farabegoli F, Papi A, Bartolini G, Ostan R, Orlandi M.
    Phytomedicine; 2010 Apr 28; 17(5):356-62. PubMed ID: 20149610
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 9.